Akari Therapeutics and Peak Bio have reached a final merger agreement, positioning themselves as partners to develop a broader portfolio with an innovative Antibody Drug Conjugate (ADC) technology base.

Administering 1.0 mg of Semaglutide led to a 24% decrease in occurrences related to kidney disease among individuals with type 2 diabetes and persistent kidney conditions.

Gilead Sciences and Merck unveil preliminary results from stage two trial revealing that a weekly oral blend of Islatravir and Lenacapavir successfully sustained control over viral levels up to the 24-week mark.

Sandoz announced that its products Wyost® and Jubbonti®, both containing denosumab-bbdz, have been approved by the US FDA.

Innate Pharma SA has declared that its pioneering research on the preclinical compound IPH45, a unique Antibody Drug Conjugate that targets Nectin-4 by inhibiting topoisomerase I.

LAVA has reported progress in clinical phase achievements by Pfizer with the drug PF-08046052, previously known as SGN-EGFRd2 or LAVA-1223.

Inborn Therapeutics: Initial Participant Treated in Early-to-Mid Stage Trial of IPH6501 for Recurrent or Resistant B-Cell Non-Hodgkin Lymphoma.

CASI Pharma Announces Encouraging Early Results for BI-1206 in Managing Persistent Forms of Non-Hodgkin’s Lymphoma in Chinese Study.

Nektar Therapeutics has launched a Phase 2b trial to assess Rezpegaldesleukin in individuals with severe forms of Alopecia Areata.

Ankyra Therapeutics has commenced dosing in its initial human trial phase, assessing the effectiveness of ANK-101, a novel anchored immunotherapy, targeting a range of solid cancers.

Novartis unveils fresh insights into Zolgensma's safety and performance, highlighting sustained and enhanced motor skills in SMA-affected children who are larger and older.

Cullinan Oncology Reveals FDA Approval for Initial Trials of Unique MICA/B Antibody, CLN-619, Targeting Advanced Multiple Myeloma Cases.